|
1
|
Barratt J and Feehally J: Primary IgA
nephropathy: New insights into pathogenesis. Semin Nephrol.
31:349–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harper SJ, Allen AC, Pringle JH and
Feehally J: Increased dimeric IgA producing B cells in the bone
marrow in IgA nephropathy determined by in situ hybridisation for J
chain mRNA. J Clin Pathol. 49:38–42. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyd JK, Cheung CK, Molyneux K, Feehally J
and Barratt J: An update on the pathogenesis and treatment of IgA
nephropathy. Kidney Int. 81:833–843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakata J, Suzuki Y, Suzuki H, Sato D, Kano
T, Horikoshi S, Novak J and Tomino Y: Experimental evidence of cell
dissemination playing a role in pathogenesis of IgA nephropathy in
multiple lymphoid organs. Nephrol Dial Transplant. 28:320–326.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mackay F and Ambrose C: The TNF family
members BAFF and APRIL: The growing complexity. Cytokine Growth
Factor Rev. 14:311–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rolink AG and Melchers F: BAFFled B cells
survive and thrive: Roles of BAFF in B-cell development. Curr Opin
Immunol. 14:266–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang M, Hase H, Legarda-Addison D,
Varughese L, Seed B and Ting AT: B cell maturation antigen, the
receptor for a proliferation-inducing ligand and B cell-activating
factor of the TNF family, induces antigen presentation in B cells.
J Immunol. 175:2814–2824. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mccarthy DD, Kujawa J, Wilson C, Papandile
A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy
KD, et al: Mice overexpressing BAFF develop a commensal
flora-dependent, IgA-associated nephropathy. J Clin Invest.
121:3991–4002. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castigli E, Scott S, Dedeoglu F, Bryce P,
Jabara H, Bhan AK, Mizoguchi E and Geha RS: Impaired IgA class
switching in APRIL-deficient mice. Proc Natl Acad Sci USA.
101:3903–3908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang
JQ, Sun LD, Sim KS, Li Y, Foo JN, et al: A genome-wide association
study in Han Chinese identifies multiple susceptibility loci for
IgA nephropathy. Nat Genet. 44:178–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schneider P, Mackay F, Steiner V, Hofmann
K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea
H, et al: BAFF, a novel ligand of the tumor necrosis factor family,
stimulates B cell growth. J Exp Med. 189:1747–1756. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gavin AL, Ait-Azzouzene D, Ware CF and
Nemazee D: DeltaBAFF, an alternate splice isoform that regulates
receptor binding and biopresentation of the B cell survival
cytokine, BAFF. J Biol Chem. 278:38220–38228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bossen C and Schneider P: BAFF, APRIL and
their receptors: Structure, function and signaling. Semin Immunol.
18:263–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mackay F and Schneider P: Cracking the
BAFF code. Nat Rev Immunol. 9:491–502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vincent FB, Morand EF and Mackay F: BAFF
and innate immunity: New therapeutic targets for systemic lupus
erythematosus. Immunol Cell Biol. 90:293–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushita T and Sato S: The role of BAFF
in autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi.
28:333–342. 2005.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eilertsen GO, Van Ghelue M, Strand H and
Nossent JC: Increased levels of BAFF in patients with systemic
lupus erythematosus are associated with acute-phase reactants,
independent of BAFF genetics: A case-control study. Rheumatology
(Oxford). 50:2197–2205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsushita T, Hasegawa M, Yanaba K, Kodera
M, Takehara K and Sato S: Elevated serum BAFF levels in patients
with systemic sclerosis: Enhanced BAFF signaling in systemic
sclerosis B lymphocytes. Arthritis Rheum. 54:192–201. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bosello S, Youinou P, Daridon C, Tolusso
B, Bendaoud B, Pietrapertosa D, Morelli A and Ferraccioli G:
Concentrations of BAFF correlate with autoantibody levels, clinical
disease activity, and response to treatment in early rheumatoid
arthritis. J Rheumatol. 35:1256–1264. 2008.PubMed/NCBI
|
|
20
|
Mariette X, Roux S, Zhang J, Bengoufa D,
Lavie F, Zhou T and Kimberly R: The level of BLyS (BAFF) correlates
with the titre of autoantibodies in human Sjögren's syndrome. Ann
Rheum Dis. 62:168–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pers JO, Daridon C, Devauchelle V, Jousse
S, Saraux A, Jamin C and Youinou P: BAFF overexpression is
associated with autoantibody production in autoimmune diseases. Ann
N Y Acad Sci. 1050:34–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moisini I and Davidson A: BAFF: A local
and systemic target in autoimmune diseases. Clin Exp Immunol.
158:155–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xin G, Shi W, Xu LX, Su Y, Yan LJ and Li
KS: Serum BAFF is elevated in patients with IgA nephropathy and
associated with clinical and histopathological features. J Nephrol.
26:683–690. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li W, Peng X, Liu Y, Liu H, Liu F, He L,
Liu Y, Zhang F, Guo C, Chen G, et al: TLR9 and BAFF: Their
expression in patients with IgA nephropathy. Mol Med Rep.
10:1469–1474. 2014.PubMed/NCBI
|
|
25
|
Mccarthy DD, Chiu S, Gao Y, Summers-Deluca
LE and Gommerman JL: BAFF induces a hyper-IgA syndrome in the
intestinal lamina propria concomitant with IgA deposition in the
kidney independent of LIGHT. Cell Immunol. 241:85–94. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Working Group of the International IgA
Nephropathy Network and the Renal Pathology Society, ; Cattran DC,
Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE,
Amore A, Barratt J, et al: The Oxford classification of IgA
nephropathy: Rationale, clinicopathological correlations, and
classification. Kidney Int. 76:534–545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kataoka H, Ohara M, Shibui K, Sato M,
Suzuki T, Amemiya N, Watanabe Y, Honda K, Mochizuki T and Nitta K:
Overweight and obesity accelerate the progression of IgA
nephropathy: Prognostic utility of a combination of BMI and
histopathological parameters. Clin Exp Nephrol. 16:706–712. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu D, Hollingshead S, Swiatlo E, Lawrence
ML and Austin FW: Rapid identification of Streptococcus pyogenes
with PCR primers from a putative transcriptional regulator gene.
Res Microbiol. 156:564–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parameswaran R, Muschen M, Kim YM, Groffen
J and Heisterkamp N: A functional receptor for B-cell-activating
factor is expressed on human acute lymphoblastic leukemias. Cancer
Res. 70:4346–4356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nardelli B, Belvedere O, Roschke V, Moore
PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG
and Hilbert DM: Synthesis and release of B-lymphocyte stimulator
from myeloid cells. Blood. 97:198–204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang XF, Yuan SL, Jiang L, Zhang XL, Li
SF, Guo Y, Wu CL and Chen JJ: Changes of serum BAFF and IL-21
levels in patients with systemic lupus erythematosus and their
clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
23:1041–1042. 2007.(In Chinese). PubMed/NCBI
|
|
33
|
Vincent FB, Northcott M, Hoi A, Mackay F
and Morand EF: Association of serum B cell activating factor from
the tumour necrosis factor family (BAFF) and a
proliferation-inducing ligand (APRIL) with central nervous system
and renal disease in systemic lupus erythematosus. Lupus.
22:873–884. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cunningham MW: Pathogenesis of group A
streptococcal infections. Clin Microbiol Rev. 13:470–511. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huard B, Arlettaz L, Ambrose C, Kindler V,
Mauri D, Roosnek E, Tschopp J, Schneider P and French LE: BAFF
production by antigen-presenting cells provides T cell
co-stimulation. Int Immunol. 16:467–475. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schneider P: The role of APRIL and BAFF in
lymphocyte activation. Curr Opin Immunol. 17:282–289. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He L, Peng X, Wang J, Tang C, Zhou X, Liu
H, Liu F, Sun L and Peng Y: Synthetic double-stranded RNA Poly
(I:C) aggravates IgA nephropathy by triggering IgA class switching
recombination through the TLR3-BAFF axis. Am J Nephrol. 42:185–197.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schmitt R, Carlsson F, Mörgelin M, Tati R,
Lindahl G and Karpman D: Tissue deposits of IgA-binding
streptococcal M proteins in IgA nephropathy and Henoch-Schonlein
purpura. Am J Pathol. 176:608–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nishikawa Y, Shibata R, Ozono Y, Ichinose
H, Miyazaki M, Harada T and Kohno S: Streptococcal M protein
enhances TGF-beta production and increases surface IgA-positive B
cells in vitro in IgA nephropathy. Nephrol Dial Transplant.
15:772–777. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu H, Peng Y, Liu F, Xiao W, Zhang Y and
Li W: Expression of IgA class switching gene in tonsillar
mononuclear cells in patients with IgA nephropathy. Inflamm Res.
60:869–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chu VT, Enghard P, Schurer S, Steinhauser
G, Rudolph B, Riemekasten G and Berek C: Systemic activation of the
immune system induces aberrant BAFF and APRIL expression in B cells
in patients with systemic lupus erythematosus. Arthritis Rheum.
60:2083–2093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Y, Enoksson S Lind, Johansson C,
Karlsson MA, Lundeberg L, Nilsson G, Scheynius A and Karlsson MC:
The expression of BAFF, APRIL and TWEAK is altered in eczema skin
but not in the circulation of atopic and seborrheic eczema
patients. PLoS One. 6:e222022011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nakajima K, Itoh K, Nagatani K,
Okawa-Takatsuji M, Fujii T, Kuroki H, Katsuragawa Y, Aotsuka S and
Mimori A: Expression of BAFF and BAFF-R in the synovial tissue of
patients with rheumatoid arthritis. Scand J Rheumatol. 36:365–372.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stohl W, Metyas S, Tan SM, Cheema GS,
Oamar B, Xu D, Roschke V, Wu Y, Baker KP and Hilbert DM: B
lymphocyte stimulator overexpression in patients with systemic
lupus erythematosus: Longitudinal observations. Arthritis Rheum.
48:3475–3486. 2003. View Article : Google Scholar : PubMed/NCBI
|
